Skill
Indication pipeline landscape
Name one indication; get its current Phase-3 drug pipeline mapped across every sponsor — each program tagged novel-agent vs repurposed-generic and overlaid with a cross-core publication-evidence maturity count — in one downloadable Excel matrix.
New to Amass? Connect Amass to Claude first
The prompt
Paste this into Claude
MASH (metabolic dysfunction-associated steatohepatitis)Use the Indication pipeline landscape skill.
Indication: MASH (metabolic dysfunction-associated steatohepatitis)Why not just ask the model?
Ask a plain model to "map the Phase-3 MASH pipeline" and it recites the few programs it remembers and invents NCT numbers, sponsors, and "publication counts" that read authoritative and are wrong.
- Plain model: half-remembered programs, fabricated NCTs, sponsors, and made-up per-program evidence counts.
- Amass: the real TrialCore rows for the live search — FELINE (losartan, Newcastle-upon-Tyne), STELLAR-3 (selonsertib, Gilead), MAESTRO-NASH (resmetirom, Madrigal), the FGF21 race (Akero efruxifermin, 89bio pegozafermin), and Lilly's retatrutide/tirzepatide SYNERGY trial — every NCT, sponsor,
overallStatusandinterventionNamesverbatim, and each trial'sreferencesBiomedCoreedge counted as a real publication-evidence overlay.
Why a skill, not a prompt?
This is a multi-step orchestration, not one question: run two TrialCore searches (the modern "metabolic dysfunction associated steatohepatitis" spelling and the classic "nonalcoholic steatohepatitis liver fibrosis" spelling), union and dedupe the result sets on nctId, then fan out one get_amass_trialcore_record per unique trial to read the referencesBiomedCore edge length, partition each row by intervention class, and assemble the sorted Excel matrix. The union is the whole point — each search returns at most limit results (10 by default) and never a total, so two wordings broaden the sample past a single relevance ranking (here 10 + 10, overlap 2 → 18 unique trials) where a one-shot prompt sees one ranking only. Packaged as a skill, you trigger the entire procedure with one line instead of pasting a brittle multi-step recipe every time.
Honest scope
A union of two relevance-ranked top-10 samples is still not a guaranteed census — each search returns at most limit results (10 by default) with no total, so unenumerated Phase-3 programs may exist; broaden by raising limit or unioning more terminology wordings. evidence_paper_count is the length of each trial's referencesBiomedCore edge — a program-maturity proxy, not an exhaustive literature search, and 0 means "no publication linked in Amass yet," not "weak program." The intervention-class tag is read client-side from interventionNames (the MCP exposes no class field). Trial status is verbatim from the registry and can lag reality by hours.
Install the skill
Add the skill to Claude
Install every Amass skill with one command, npx skills add amass-technologies/public-skills or download the SKILL.md from GitHub and add it to Claude (Settings → Capabilities → Skills, or drop it in your Claude Code skills directory). Then paste the prompt above to trigger it.
More from the library
Keep exploring
| Short name | Source id | Registry | Copy of |
|---|---|---|---|
| Acute, 50/75 mg vs placebo | NCT04072354 | ClinicalTrials.gov | |
| ↳ EUCTR2019-000470-36-BG | EU CTR | NCT04072354 | |
| Acute, 75/100 mg vs placebo | NCT04092686 | ClinicalTrials.gov |
Watchlist Monitor
Name the trials, papers, approvals or drugs you need to follow; get one Excel board that re-reads them through Amass at every check and tells you exactly what changed: status, dates, enrollment, results posted, label revisions, retractions, new links.

Landscape Monitor
Name a field; get it mapped across trials, papers, patents, drugs, genes and approvals into a landscape page with charts, a workbook and a one-page briefing, every record screened with its reason. Ask for an update later to see what is new and what changed.
| kinase | kinase_family_chembl_leaf | small_molecule_tractability | protac_tractability |
|---|---|---|---|
| PLK1 | Other protein kinase PLK family | Advanced Clinical | predictive-only |
| WEE1 | Other protein kinase WEE family | Advanced Clinical | predictive-only |
| CDK1 | CMGC protein kinase CDK5 subfamily | Advanced Clinical | predictive-only |
Target prioritization matrix
A general, interview-driven target-discovery workbench: name the biology and the modality you care about, and get back a scored table of candidate targets — druggability, essentiality, genetic constraint, curated safety, and the real number of drugs already targeting each — assembled from GeneCore intelligence and DrugCore/TrialCore/BiomedCore/PatentCore cross-links.
Run it yourself
Connect Amass to Claude and paste the prompt.
The connector takes about a minute to add, then this workflow runs on your own inputs.
- Data
- No training on your data
- Hosting
- EU-hosted, enterprise
- Isolation
- Tenant-isolated by architecture
- Certification
- ISO 27001, SOC 2, NIS2: in motion